PIK3CA and cancer: A recent trial of the mTOR inhibitor, everolimus, in combination with cisplatin given preoperatively to TNBC patients with residual disease following preoperative anthracycline/taxane showed responses to therapy in patients whose cancers had a PIK3CA mutation or a germline PALB2 mutation [55].